In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...

The UK government will contribute up to £50 million of new investment into the scheme, with Lilly contributing up to £35 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...

“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

Jazz Pharmaceuticals has paid $10m upfront for a KRAS inhibitor programme from UK biotech Redx Pharma that extends its targeted cancer therapy pipeline.

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...